Signal Genetics is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma (MM) performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics’ flagship product - MyPRS (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on nearly 10,000 MM patients who received their care at UAMS.
Signal Genetics offer the MyPRS test out of its state-of-the-art, CLIA ...
Signal Genetics is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma (MM) performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics’ flagship product - MyPRS (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on nearly 10,000 MM patients who received their care at UAMS.
Signal Genetics offer the MyPRS test out of its state-of-the-art, CLIA certified reference laboratory located in Little Rock, AR. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them.
The mission of Signal Genetics is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions.
-
Number of Employees:
0-25
-
Annual Revenue:
$0-1 Million